Type 2 Diabetes Trial, Recruiting NCT06730113 Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT06730113
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Young people with Type 2 diabetes (ages 12–25):

  • People aged 12 to 25 who have been diagnosed with Type 2 diabetes based on blood sugar or A1c test results, along with at least one relevant risk factor such as family history of diabetes, obesity, certain ethnic backgrounds, or other related health conditions — or who have verified medical records showing a Type 2 diabetes diagnosis made at age 25 or younger

Young people who are overweight or have obesity (ages 12–25):

  • People aged 12 to 17 whose BMI is at or above the 85th percentile for their age and sex (overweight or obese range)
  • People aged 18 to 25 whose BMI is 25 or above
  • People in this group who also have prediabetes (based on slightly elevated blood sugar or A1c levels) may still be eligible

Healthy lean young people (ages 12–25):

  • People aged 12 to 17 whose BMI is at or below the 85th percentile for their age and sex
  • People aged 18 to 25 whose BMI is between 18 and 24.99
  • People whose A1c level is below 5.7%

Biological parents of enrolled participants:

  • Biological parents of young people already enrolled in the trial (based on self-report)

Who may not be able to join:

For young people with Type 2 diabetes, those who are overweight, or healthy lean participants:

  • People who have Type 1 diabetes, or who test positive for more than 2 diabetes-related antibodies
  • People with medical, psychiatric, or thinking/cognitive conditions that researchers believe would make it difficult to follow the study procedures (note: certain obesity-related conditions such as high blood pressure, high cholesterol, sleep apnea, and a specific liver condition are allowed)
  • People with serious illnesses thought to affect metabolism, including moderate to severe kidney disease, congenital heart disease, Cushing's syndrome, cancer, or other metabolic conditions linked to diabetes or excess weight
  • People enrolled at the NIH location who have food allergies, intolerances, or eating patterns that would prevent them from eating the study-specific meals
  • People who are unwilling to follow all study procedures and lifestyle guidelines for the full duration of the study
  • People who are pregnant at the time of their screening visit
  • People with significant anaemia or a low red blood cell level for their age and sex
  • People in the overweight/obesity group who meet the diagnostic criteria for Type 2 diabetes (as described in the inclusion criteria above)

Additional restrictions for healthy lean participants only:

  • People currently taking prescription or non-prescription medications (some exceptions may apply, such as topical medications, vitamins, and hormonal contraceptives — other exceptions may be considered by researchers)
  • People who have used medications or supplements that affect blood sugar or fat metabolism within the past 2 months (for example, niacin, fish oil, or red yeast rice)
  • People with a history of diabetes or abnormal blood sugar levels
  • People with certain abnormal results on screening blood tests, including elevated liver enzymes, sugar in the urine, or reduced kidney function
  • People who meet the diagnostic criteria for Type 2 diabetes

For biological parents:

  • No exclusion criteria apply to this group

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Stephanie T Chung, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phone: (240) 383-9379

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
12 March 2025
Est. completion
31 October 2033

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Pulse wave velocity (PWV); Augmentation index (Aix); Pulse wave velocity (PWV); Augmentation index (Aix)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov